In the news
For 2021, cell, gene therapies make Prime’s “Drugs to Watch” list
April 16, 2021AJMC
Related news
In the news
May 29, 2022
Biosimilars Can Help Lower Patient Drug Costs When the Right Teams Come Together: Prime Therapeutics Executive
Managed Healthcare Executive
In the news
May 5, 2022
Prime Therapeutics buying Magellan Health’s pharma business for $1.35 billion
Minneapolis/St. Paul Business Journal